A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
Clinical trial NCT06491914 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06491914
- Sponsor
- Regeneron Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-07-24
- Primary completion
- 2025-08-26
- Enrollment
- 1118
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.